1 Border T,Kraling BM.Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer[J].Cancer Res,2000,60(7):1878-1886. 2 Chen X,Zhang JG,Zhao LC,et al.Effects of VEGF-D and VEDFR-3 in breast cancer lymph vessel metastasis[J].Progress in Modern Biomedicine,2006,6(9):21-23. 3 Shevchenko I,Karakhanova S,Soltek S,et al.Low-dose emcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer[J].Int J Cancer,2013,133(1):98-107. 4 Chen CS,Doloff JC,Waxman DJ.Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression[J].Neoplasia,2014,16(1):84-96. 5 Shaked Y,Emmengger U,Man S,et al.The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity[J].Blood,2005,106(9):3058-3061. 6 Voloshin T,Voest EE,Shaked Y.The host immunological response to cancer therapy:an emerging concept in tumor biology[J].Exp Cell Res,2013,319(11):1687-1695. 7 Katz OB,Shaked Y.Host effects contributing to cancer therapy resistance[J].Drug Resist Updat,2015,19:33-42. 8 Shaked Y.Balancing efficacy of and host immune responses to cancer therapy:the yin and yang effects[J].Nat Rev Clin Oncol,2016,13(10):611-626. 9 Ge Y,Domschke C,Stoiber N,et al.Metronomic cyclophosphamide treatment in metastasized breast cancer patients:immunological effects and clinical outcome[J].Cancer Immunol Immunother,2012,61(3):353-362. 10 Tongu M,Harashima N,Monma H,et al.Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo[J].Cancer Immunol Immunother,2013,62(2):383-391. 11 Muthusamy P,Chary KV,Nalini GK.Metronomic chemotherapy:seems prowess to battle against cancer in current scenario[J].J Clin Diagn Res,2016,10(11):9-13. 12 Rajasekaran T,Ng QS,Tan DS,et al.Metronomic chemotherapy:A relook at its basis and rationale[J].Cancer Lett,2017,388:328-333. |